title: Assessment of the response in vivo and in vitro of Plasmodium falciparum to sulphadoxine-pyrimethamine in the malarious areas of Iran.
abstract: Studies of drug resistance of Plasmodium falciparum cases from SE Iran were carried out in vivo and in vitro during 1990-91. In a study of 26 chloroquine-resistant infections, using amodiaquine (25 mg kg-1 over 3 days), followed by two-thirds of the standard dose of sulphadoxine-pyrimethamine, six cases were resistant at the RI(3) and RII(3) levels. An additional study testing the standard dose of sulphadoxine-pyrimethamine in 43 chloroquine-resistant cases revealed five (11.6%) resistant at the RI(2) and RII(3) levels. Six of the above resistant infections were contracted in Hormozgan, three in Sistan-Baluchestan, one in Kerman provinces of Iran and one in Pakistan. In five of 22 successful in-vitro tests, carried out on different isolates, the parasites grew to schizonts (> or = 8 nuclei) in the wells containing 1000 pmol sulphadoxine and 12.5 pmol pyrimethamine, indicative of resistance.
authors.affiliation: School of Public Health, Teheran University of Medical Sciences, Iran.
authors.forename: G H
authors.initials: GH
authors.lastname: Edrissian
authors.forename: A
authors.initials: A
authors.lastname: Afshar
authors.forename: A
authors.initials: A
authors.lastname: Sayedzadeh
authors.forename: G
authors.initials: G
authors.lastname: Mohsseni
authors.forename: M T
authors.initials: MT
authors.lastname: Satvat
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000655:Amodiaquine / Q000627:therapeutic use; D000818:Animals; D002648:Child; D002675:Child, Preschool; D002738:Chloroquine / Q000494:pharmacology; D004338:Drug Combinations; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007223:Infant; D007492:Iran; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000469:parasitology; D008297:Male; D008875:Middle Aged; D010963:Plasmodium falciparum / Q000187:drug effects*; D011739:Pyrimethamine / Q000494:pharmacology* / Q000627:therapeutic use; D011803:Quinine / Q000627:therapeutic use; D012044:Regression Analysis; D013413:Sulfadoxine / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D004338:Drug Combinations; D000655:Amodiaquine; D013413:Sulfadoxine; D002738:Chloroquine; D011803:Quinine; D011739:Pyrimethamine